Recruiting Clinical Trials

CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

By April 24, 2017 No Comments


Solid Tumor|Advanced Cancer|ColoRectal Cancer|Endometrial Cancer|Gastric Cancer|Hepatocellular Cancer|Nonsmall Cell Lung Cancer|Mesothelioma|Ovarian Cancer|Renal Cancer|Nasopharyngeal Cancer|Esophageal Cancer|Gastroesophageal Junction Adenocarcinoma

Estimated Enrollment: 50

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: CBT-501-01

Study First Received: January 30, 2017

Last Updated: March 30, 2017

Estimated Primary Completion Date: February 2018


Primary Outcome Measures:

Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors|Determine the recommended Phase 2 dose and schedule|Area under the plasma concentration versus time curve (AUC)|Maximum plasma concentration|Time to reach Cmax|Overall Objective Response Rate|Duration of Response|Time to Response|Disease Control Rate|Progression Free Survival

Sponsors and Collaborators:

CBT Pharmaceuticals, Inc.|Novotech (Australia) Pty Limited

Website Link:

Leave a Reply

Call Now